Razadyne/Reminyl (Alzheimer's Disease) - Forecast and Market Analysis to 2022 - PR Newswire (press release)

LONDON, Dec. 26, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Razadyne/Reminyl (Alzheimer's Disease) - Forecast and Market Analysis to 2022 ^[1]

Razadyne/Reminyl (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, "Razadyne/Reminyl (Alzheimer's Disease) - Forecast and Market Analysis to 2022". There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Razadyne (also known as Reminyl) is a reversible, competitive AChEI indicated for the treatment of mild to moderate AD. The exact MOA of galantamine is not known; however, it is thought to exert its effects by enhancing cholinergic function as a result of an increase in the concentration of ACh through reversible inhibition of hydrolysis by cholinesterase.

Scope

- Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Razadyne / Reminyl including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Razadyne / Reminyl for the top eight countries from 2012 to 2022.

- Sales information covered for France, Germany, Italy, Spain, the UK, Japan, China and India.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for AD

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of Razadyne / Reminyl performance

- Obtain sales forecast for Razadyne / Reminyl from 2012-2022 in top eight countries (France, Germany, Italy, Spain, the UK, Japan, China and India)

Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

3 Disease Overview 11

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 15

3.2 Symptoms 27

4 Disease Management 29

4.1 Diagnosis 29

4.1.1 Probable Alzheimer's Disease Dementia 30

4.1.2 Possible AD Dementia 31

4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 31

4.1.4 Possible Alzheimer's Dementia with Evidence of the Alzheimer's Disease Pathophysiological Process 32

4.1.5 Preclinical AD 32

4.1.6 Mild Cognitive Impairment 33

4.2 Treatment Overview 35

5 Competitive Assessment 38

5.1 Overview 38

5.2 Strategic Competitor Assessment 38

6 Razadyne/ Reminyl 41

6.1 Overview 41

6.2 Efficacy 42

6.3 Safety 44

6.4 SWOT Analysis 44

6.5 Forecast 45

7 Appendix 46

7.1 Bibliography 46

7.2 Abbreviations 51

7.3 Methodology 54

7.4 Forecasting Methodology 54

7.4.1 Diagnosed AD patients 55

7.4.2 Percent Drug-treated Patients 56

7.4.3 General Pricing Assumptions 56

7.4.4 Individual Drug Assumptions 58

7.4.5 Generic Erosion 58

7.5 Physicians and Specialists Included in this Study 59

7.6 About the Authors 60

7.6.1 Author 60

7.6.2 Global Head of Healthcare 61

7.7 About GlobalData 62

7.8 Disclaimer 62

List of Tables

Table 1: Symptoms of AD 28

Table 2: Guidelines for the Treatment of AD 35

Table 3: Most Prescribed Drugs for AD by Class in the Global Markets, 2012 36

Table 4: Leading Branded Treatments for AD, 2013 39

Table 5: Product Profile – Razadyne 42

Table 6: Razadyne SWOT Analysis, 2013 44

Table 7: Global Sales Forecasts ($m) for Razadyne, 2012–2022 45

List of Figures

Figure 1: Atrophy of the Brain in AD 17

Figure 2: Key Pathological Features in AD Versus a Healthy Neuron 19

Figure 3: Non-Amyloidogenic Metabolism of APP 21

Figure 4: Amyloidogenic Metabolism of APP 22

Figure 5: Neurofibrillary Tangles 24

Figure 6: Oxidative Damage Due to Free Radicals 26

Figure 7: Strategic Competitor Assessment of the Marketed Products in AD, 2013 40

Read the full report:

Razadyne/Reminyl (Alzheimer's Disease) - Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/razadyne_reminyl_alzheimers_disease_forecast_market_analysis_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ^[2] ^[3]

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: www.reportbuyer.com ^[4] ^[5]